Thermo Fisher Scientific Accounts Receivable decreased by 0.1% to $8.90B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.7%, from $8.19B to $8.90B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 9.2% CAGR.
An increase relative to revenue may signal slowing collections or aggressive sales terms; a decrease suggests efficient billing and collection cycles.
The total amount of credit extended to customers for products and services already delivered, adjusted for potential bad...
Enterprise-focused peers like Oracle or SAP show similar patterns based on quarterly sales cycles.
accounts_receivable_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.48B | $5.56B | $7.98B | $7.89B | $7.75B | $7.67B | $8.12B | $7.92B | $8.02B | $8.37B | $8.22B | $7.93B | $7.94B | $8.26B | $8.19B | $8.46B | $8.59B | $8.91B | $8.90B |
| QoQ Change | — | +1.5% | +43.5% | -1.1% | -1.8% | -1.0% | +5.8% | -2.4% | +1.2% | +4.4% | -1.8% | -3.5% | +0.2% | +3.9% | -0.8% | +3.2% | +1.6% | +3.7% | -0.1% |
| YoY Change | — | — | — | — | +41.4% | +38.0% | +1.7% | +0.4% | +3.5% | +9.1% | +1.3% | +0.1% | -0.9% | -1.4% | -0.4% | +6.6% | +8.2% | +7.9% | +8.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.